Dense Deposit Disease (DDD) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Dense deposit is a rare autoimmune disease that mainly affects kidney function. The etiology involved is due to the harmful genetic alteration called pathogenic variants. Genetic alterations can occur suddenly due to environmental factors or from parents to offspring. This disease can occur either before birth or at any time during your life. Seven cases of DDD are found in kidney-transplanted patients with C3 glomerulopathy, which is a common occurrence in kidney transplant recipients. It is identified by the renal biopsy test, also known as ‘immunofluorescence.’ The clinical features of Dense Deposit Disease may vary. Several cases are identified through proteinuria, mainly in a hematuria and nephrotic range. Serum C3 levels (less)and C4 serum(normal) are essential for diagnosing this disease. The differential diagnosis may be challenging due to the loss of immunoglobulin deposits and consistent accumulation of C3 inside the infection-related disease. Treatment involved in Dense Deposit Disease aims to regulate blood pressure and decrease proteinuria. According to the KDIGO guidelines, preventive steps are suggested for all patients. In contrast, immunosuppressive is allowed for patients with moderate and critical disease (proteinuria > 1 g/day, hematuria, or kidney function decline for at least 6 months).
Thelansis’s “Dense Deposit Disease (DDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dense Deposit Disease (DDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Dense Deposit Disease (DDD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Dense Deposit Disease (DDD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
